BUSINESS SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Product Revenues [Table Text Block]

Product revenues were as follows:

	Three Months Ended March 31,
Dollars in Millions	2015		2014
Virology
Baraclude (entecavir)	$	340	$	406
Hepatitis C Franchise(a)	264		—
Reyataz (atazanavir sulfate) Franchise	294		344
Sustiva (efavirenz) Franchise(b)	290		319
Oncology
Erbitux* (cetuximab)	165		169
Opdivo (nivolumab)	40		—
Sprycel (dasatinib)	375		342
Yervoy (ipilimumab)	325		271
Neuroscience
Abilify* (aripiprazole)(c)	554		540
Immunoscience
Orencia (abatacept)	400		363
Cardiovascular
Eliquis (apixaban)	355		106
Mature Products and All Other(d)	639		951
Total Revenues	$	4,041	$	3,811

*	Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information can be found at the end of this quarterly report on Form 10-Q.
(a)	Includes Daklinza (daclatasvir) revenues of $180 million and Sunvepra (asunaprevir) revenues of $84 million for the three months ended March 31, 2015.
(b)	Includes alliance and other revenue of $251 million and $272 million for the three months ended March 31, 2015 and 2014, respectively.
(c)	Includes alliance and other revenue of $508 million and $441 million for the three months ended March 31, 2015 and 2014, respectively.
(d)	Includes Diabetes Alliance revenues of $54 million and $179 million for the three months ended March 31, 2015 and 2014, respectively. See "—Note 3. Alliances" for further information on the diabetes business divestiture.